Biossil Hits Unicorn Status With OpenAI-Led Round

Toronto biotech Biossil raised $153 million USD at a $1 billion valuation, led by the OpenAI Startup Fund, with Founders Fund and others participating. The company buys failed drug candidates and revives them using AI. It exited stealth in April with $70 million and will use the new funds to expand clinical development and acquire more drug assets.